Seattle Genetics was founded in nineteen ninety-nine by Clay Siegall with the aim of researching about human antibodies. The company has been manipulating and packaging drugs since when it was founded. The antibodies from the company can connect to other things especially a therapy. The antibodies are essential in destroying a cancer cell by providing a toxic payload.
Seattle Genetics is categorized among the big leagues. The company has a market value of approximately ten billion dollars and has employed nine hundred employees. Seattle Genetics has been ranked as one of the largest biotech in Washington DC. Clay Siegall is planning to make investments that will make the company grow and employ two hundred more employees.
The company has come up with a drug known as Adcetris that treat Hodgkin Lymphoma. Hodgkin Lymphoma is cancer that attacks the lymph system thus spreading to other organs. Siegalls’ idea is to establish a global and multiproduct oncology company that will no longer sell drugs to another larger company as other firms in the biotech industry have been doing. He is also doing international marketing of the company’s newer drugs. Siegall has opened an office in Switzerland to help his company do international marketing on its own.
Clay has spent up to two billion dollars to purchase the worldwide rights with the aim of marketing a cancer drug that was developed by Immunomedics based in New Jersey. This was a way of showing his commitment to the international market. Seattle genetics continues to grow and achieve greater success despite the fact that it is only eighteen years old.
About Dr.Clay Siegall.
Clay is an experienced man with a vast knowledge of the biotech industry. He has used his experience to build various antibody therapies that deal with cancer. Some of the therapies include;
- ADCETRIS (brentuximab vedotin)
This therapy was approved in twenty eleven by the United States Food and Drug Administration. Seattle Genetics under the leadership of Clay Siegal has raised over six hundred and seventy-five million dollars through capital-raising activities and private financings .Dr. Siegall had worked with the Bristol-Myers Squibb Pharmaceutical Research Institute from nineteen ninety-one to nineteen ninety-seven before he founded Seattle Genetics. Siegall is an author to over seventy publications and proudly owns fifteen patents. Clay holds a Doctor of Philosophy in Genetics which he received from the prestigious University of George Washington. He also holds a Bachelor’s Degree in Zoology which he received from Maryland University.